Chrong-Reen Wang1, Yi-Shan Tsai2, Cheng-Han Lee3

1Department of Internal Medicine, Division of Rheumatology, National Cheng Kung University Hospital, Tainan, Taiwan
2Department of Medical Imaging, National Cheng Kung University Hospital, Tainan, Taiwan
3Department of Internal Medicine, Division of Cardiology, National Cheng Kung University Hospital, Tainan, Taiwan

Heart involvement with cardiac insufficiency is a cause of early death and is associated with poor prognosis in eosinophilic granulomatosis with polyangiitis (EGPA),[1] a disease classified as antineutrophil cytoplasmic antibody-associated vasculitis. Although cyclophosphamide (CYC) is required to induce disease remission in the presence of cardiac insufficiency,[2] there is well-known dosage-related cardiotoxicity in addition to increased risks of infertility, infection, and malignancy.[3] Limited efficacy with significant adverse effects of CYC therapy has prompted the search for effective and secure alternative therapeutics in EGPA. Eosinophils play a central role in the pathogenesis, and the activation and recruitment of these cells are mainly mediated by interleukin (IL)-5, a key therapeutic target in EGPA.[4] Nevertheless, mepolizumab (MEP), an anti-IL-5 monoclonal antibody, has been suggested in the induction treatment of EGPA with nonsevere diseases, such as asthma and sinonasal manifestations.[5] Herein, we report a case of EGPA endomyocarditis with cardiac insufficiency under MEP induction therapy, leading to normalized cardiac dysfunction and disease remission with sparing use of glucocorticoids (GCs).

A 36-year-old female presented to our hospital with dyspnea and palpitation that had lasted for one month. Based on bronchial asthma, mononeuritis multiplex, and blood eosinophilia with extravascular infiltration,[6] the patient had received an EGPA diagnosis a year ago. She was in remission under combined CYC/GC induction therapy. At admission, laboratory tests revealed positive antimyeloperoxidase and increased levels of eosinophils (7,140/µL) and cardiac biomarkers. Echocardiography and magnetic resonance imaging demonstrated impaired left ventricular ejection fraction, myocardial edema, and diffuse mid-wall and endocardial enhancement, indicating endomyocarditis with cardiac insufficiency (Figure 1a, b). Holter monitoring revealed paroxysmal atrial tachycardia and atrial/ ventricular premature contractions. Glucocorticoid and cardiac supporting agents were prescribed for the disease relapse with heart involvement. The patient refused CYC induction therapy due to the side effects from earlier exposure. There was a more than 90% decrease in blood eosinophilia with stationary follow-up counts less than 150/µL following subcutaneous injection of 100 mg MEP quadriweekly (i.e. one time every four weeks). Twelve months after therapy, in addition to absent clinical symptoms and normalized biomarker levels, cardiac examinations showed normalized rhythm and left ventricular ejection fraction, resolved myocardial edema, and reduced mid-wall and endocardial delayed gadolinium enhancement (Figure 1c, d). No adverse effects were observed. The patient had a complete remission with sparing daily use of GCs.

Persistent blood and tissue eosinophilia can damage the myocardium and endocardium, causing eosinophilic myocarditis/endomyocarditis in EGPA.[3,7] In our patient, the improvement in endomyocarditis appeared to be mediated by an action mechanism of reduced eosinophilia under anti-IL-5 therapy. Mepolizumab injection has indications for eosinophilic asthma and hypereosinophilic syndrome quadriweekly (i.e. one time every four weeks) at 100 and 300 mg, respectively. This medication was approved in EGPA based on a phase III trial comparing a 300 mg regimen with a placebo.[8] Since there were no available dose-escalation studies, it remains to be determined whether 100 mg is inferior to the 300 mg regimen. Nevertheless, in practice, most patients with EGPA receive a 100 mg regimen.[9,10] A recent European retrospective study has demonstrated similar efficacy and higher safety of 100 mg dose compared to 300 mg for EGPA therapy.[10]

Citation: Wang CR, Tsai YS, Lee CH. Mepolizumab therapy improves endomyocarditis in seropositive eosinophilic granulomatosis with polyangiitis. Arch Rheumatol 2023;38(1):159-161.

Ethics Committee Approval

The Institutional Review Board of our hospital approved this study (IRB number B-ER-105- 108, human study amendment approval on 2022 March 16 with research term extending till 2025 April 30).

Author Contributions

Study conception and design: W.C.R.; Acquisition of data: W.C.R., T.Y.S., L.C.H.; Analysis and interpretation of data: W.C.R., T.Y.S., L.C.H.: All authors were involved in drafting the article and approved the final version to be published.

Conflict of Interest

The authors declared no conflicts of interest with respect to the authorship and/or publication of this article.

Financial Disclosure

The authors received no financial support for the research and/or authorship of this article.


The authors are indebted to physicians and nurses at our hospital involved in the management of this reported patient.


  1. Moosig F, Bremer JP, Hellmich B, Holle JU, HollUlrich K, Laudien M, et al. A vasculitis centre based management strategy leads to improved outcome in eosinophilic granulomatosis and polyangiitis (Churg-Strauss, EGPA): Monocentric experiences in 150 patients. Ann Rheum Dis 2013;72:1011-7. DOI: 10.1136/annrheumdis-2012-201531
  2. Groh M, Pagnoux C, Baldini C, Bel E, Bottero P, Cottin V, et al. Eosinophilic granulomatosis with polyangiitis (Churg-Strauss) (EGPA) Consensus Task Force recommendations for evaluation and management. Eur J Intern Med 2015;26:545-53. DOI: 10.1016/j.ejim.2015.04.022
  3. Gioffredi A, Maritati F, Oliva E, Buzio C. Eosinophilic granulomatosis with polyangiitis: An overview. Front Immunol 2014;5:549. DOI: 10.3389/fimmu.2014.00549
  4. Trivioli G, Terrier B, Vaglio A. Eosinophilic granulomatosis with polyangiitis: Understanding the disease and its management. Rheumatology (Oxford) 2020;59(Suppl 3):iii84-iii94. DOI: 10.1093/rheumatology/kez570
  5. Chung SA, Langford CA, Maz M, Abril A, Gorelik M, Guyatt G, et al. 2021 American College of Rheumatology/Vasculitis Foundation guideline for the management of antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheumatol 2021;73:1366-83. DOI: 10.1002/art.41773
  6. Grayson PC, Ponte C, Suppiah R, Robson JC, Craven A, Judge A, et al. 2022 American College of Rheumatology/European Alliance of Associations for Rheumatology classification criteria for eosinophilic granulomatosis with polyangiitis. Arthritis Rheumatol 2022;74:386-92. DOI: 10.1136/annrheumdis-2022-222362
  7. Cheung CC, Constantine M, Ahmadi A, Shiau C, Chen LYC. Eosinophilic myocarditis. Am J Med Sci 2017;354:486-92. DOI: 10.1016/j.amjms.2017.04.002
  8. Wechsler ME, Akuthota P, Jayne D, Khoury P, Klion A, Langford CA, et al. Mepolizumab or placebo for eosinophilic granulomatosis with polyangiitis. N Engl J Med 2017;376:1921-32. DOI: 10.1056/NEJMoa1702079
  9. Detoraki A, Tremante E, Poto R, Morelli E, Quaremba G, Granata F, et al. Real-life evidence of low-dose mepolizumab efficacy in EGPA: A case series. Respir Res 2021;22:185. DOI: 10.1186/s12931-021-01775-z
  10. Bettiol A, Urban ML, Dagna L, Cottin V, Franceschini F, Del Giacco S, et al. Mepolizumab for Eosinophilic Granulomatosis With Polyangiitis: A European Multicenter Observational Study. Arthritis Rheumatol 2022;74:295-306. DOI: 10.1002/art.41943